Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center
Conclusion: Patients with mRCC treated via the PHS had worse overall survival, possibly due to poorer prognosis at presentation and less drug access.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
More News: Brazil Health | Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Study | Urology & Nephrology